UVLrx Therapeutics Receives CE Marking for Intravenous UV Light Therapy Device
UVLrx Therapeutics announces that it has received CE marking to commercially sell its UVLrx 1500 multi-wavelength, intravenous light therapy system in the European Union. The UVLrx 1500 System offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths. Using the company’s patent pending Dry Light Adapter™ and a standard I.V. catheter, the UVLrx 1500 eliminates the need for removal of blood from the body.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150928006674/en/
The UVLrx 1500 System is a LED-based medical device that administers multiple light wavelengths through a peripheral I.V. catheter to the passing blood supply. (Photo: Business Wire)
UVLrx’s CE marking covers the following indications:
- Reduction of pain
- Reduction of pathogens in the blood
- Reduction of inflammation
- Immune system modulation
- Improved ATP synthesis
- Improved wound healing
- Improved blood oxygen transport
- Improved circulation
“We are pleased to have received the CE mark and are bringing the UVLrx 1500 System to the European market,” says Michael Harter, CEO and president of UVLrx. “The breadth of indications covered by our CE points to a bright future for this treatment and for the patients who will benefit from the technology.”
The UVLrx 1500 System is a LED-based medical device that administers multiple wavelengths through a peripheral I.V. catheter to the passing blood supply. Each wavelength was chosen as a result of its unique therapeutic qualities. Red light has anti-inflammatory and immune system-boosting capabilities, while green is shown to improve red blood cell function. UVA has a potent antimicrobial effect. Because skin inhibits the penetration of light, UVLrx delivers these wavelengths concurrently through a standard one-inch, 20-gauge I.V. catheter.
Once an I.V. site is established, the system calibration and setup take a matter of minutes. A patient sits comfortably during the 60-minute treatment, which includes 30 minutes of red and UVA wavelengths followed by 30 minutes of red and green wavelengths. For hospitals, outpatient surgery centers and private practice physicians, the UVLrx Treatment System seamlessly integrates with the standards of care for a variety of indications and conditions.
Ultraviolet Blood Irradiation has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating Lupus. Routinely used in hospitals worldwide, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion in drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. The UVLrx 1500 Treatment System's innovations include multi-wavelength light delivery and a delivery system that requires only one intravenous entry point, eliminating requirements to remove and transfuse blood as well as the need for constant personnel supervision.
About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to educating the world about the clinically proven benefits of the light wavelengths utilized in UVLrx technology. With its unique, multi-wavelength therapy system, UVLrx is executing its mission to provide safe and effective therapeutic solutions for a variety of medical issues. For more information on UVLrx, please visit www.uvlrx.com.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
Kennedy Wilson and Kennedy Wilson Europe Real Estate Plc Complete Merger, Creating $8 Billion Global Real Estate Company20.10.2017 10:00 | Pressemelding
Global real estate investment company Kennedy-Wilson Holdings, Inc. (NYSE:KW) (“KW”) today announced the completion of its merger with Kennedy Wilson Europe Real Estate Plc (LSE:KWE) (“KWE”). The transaction creates a leading global real estate investment and asset management platform with an $8 billion enterprise value. “This transformative combination with KWE represents an exciting new chapter for our company,” said William J. McMorrow, Chairman and CEO of KW. “We are moving towards a simplified corporate structure that provides more recurring income from stable property cash flows and greater upside potential from value-enhancing initiatives worldwide. We are well positioned for future growth and to continue our track record of generating attractive risk-adjusted returns on our invested capital.” “We are thrilled to combine the financial strength of KW and KWE to continu
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom